Method for activating the lipid catabolic metabolism in enteric epithelium and improving the lipid metabolism in enteric epithelium

Abstract

Disclosed are a method for activating lipid metabolism in the small intestine epithelium and also a method for promoting accumulation of fatty acids into the small intestine epithelium, each of which features administering an effective amount of a diacylglycerol. Also disclosed are methods for improving various symptoms in diabetes, which have ingesting a diacylglycerol. Ingestion of the diacylglycerol leads to accumulation of the fatty acids in the small intestine. The fatty acids so accumulated promote induction of β-oxidation, thereby not only activating lipid catabolism but also making it difficult to allow lipids to accumulate as triacylglycerols. This series of actions eventually results in development of lowering action for blood remnant-like lipoprotein level and also lowering action for blood leptin level, and hence, lipid metabolism is improved. Further, energy consumption is enhanced by promoting the induction of β-oxidation and activating lipid catabolism.

1 - 34 . (canceled)  
     
     
         35 . A method for lowering HOMA-R in a diabetic comprising administering an effective amount of a diacylglycerol to a diabetic patient.  
     
     
         36 . The method according to  claim 35 , wherein 15 to 90 wt. % of constituent fatty acids of said diacylglycerol comprise ω3 unsaturated fatty acids.  
     
     
         37 . The method according to  claim 35 , wherein 1,3-diacylglycerols in said diacylglycerol amount to at least 50 wt. % of the whole diacylglycerol.  
     
     
         38 . The method according to  claim 35 , wherein constituent fatty acids of said diacylglycerol are comprises of 70 to 100 wt. % of unsaturated fatty acids.  
     
     
         39 . The method according to  claim 38 , wherein said constituent fatty acids comprise cis-form unsaturated fatty acids, trans-form unsaturated fatty acids and saturated fatty acids in a ratio of cis-form unsaturated/trans-form unsaturated+saturated fatty acids of 6 or greater.  
     
     
         40 . The method according to  claim 35  wherein constituent fatty acids comprise 5% or lower of trans-form unsaturated fatty acids.  
     
     
         41 . The method according to  claim 35  wherein constituent fatty acids comprise 5% or lower of saturated fatty acids.  
     
     
         42 . The method according to  claim 35 , wherein said diacylglycerol is administered as a component of an oil or fat composition which further comprises 0 to 85 wt. % of triacylglycerol.  
     
     
         43 . The method according to  claim 35 , wherein said diacylglycerol is administered as a component of an oil or fat composition which further comprises 0 to 30 wt. % of monoacylglycerol.  
     
     
         44 . The method according to  claim 35 , wherein said diacylglycerol is administered as a component of an oil or fat composition which further comprises 0.05 to 20 wt. % of phytosterol.  
     
     
         45 . The method according to  claim 35 , wherein said diacylglycerol is administered at a daily dosage of from 0.1 to 25 g.